Dermatology
Conference Coverage
Researchers tease apart multiple biologic failure in psoriasis, PsA
Patients failing two or more biologic agents of different mechanistic classes “are really suffering. We need to have better guidelines and...
Latest News
Body dysmorphic disorder diagnosis guidelines completed in Europe
New guidelines for body dysmorphic disorder are designed to facilitate diagnosis and choice of intervention.
Latest News
Most patients with psoriasis not engaged in highly shared decision-making
“It is important to construct a framework for carrying out SDM with patients with psoriasis to enhance clinician-patient communication and improve...
From the Journals
Dupilumab-associated lymphoid reactions require caution
In cases involving unexpected responses or atypical presentations, clinicians must have a low threshold for stopping dupilumab.
Latest News
More phase 3 data support use of nemolizumab for prurigo nodularis
"Now I hope you understand why we are so excited," said lead investigator Sonja Ständer, MD.
Latest News
Birch bark–derived treatment reduces daily dressings in patients with epidermolysis bullosa
Despite being approved in Europe, Oleogel-S10 has not yet been approved to treat EB in the United States.
Latest News
Survey finds oral minoxidil shortage in Washington-area pharmacies
The drug’s popularity as a hair-loss treatment may be leading to decreased supplies.
Latest News
AI flagged skin cancer with near-perfect accuracy, in UK study
The researchers tested the AI by integrating it into a clinical diagnosis process - anticipating a future in which AI helps doctors catch skin...
News from the FDA/CDC
FDA OKs first ustekinumab biosimilar
The drug has also been granted an interchangeability designation and has been approved for six indications.
News
FDA approves second treatment for adults with hidradenitis suppurativa
Secukinumab was previously approved by the FDA for treatment of moderate to severe plaque psoriasis in adults, and several other indications.
Latest News
Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications
Of the 35 trials studied, most involved patients with atopic dermatitis.